Skip to content

13F-HR filed by RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. filed this 13F-HR for the quarter ended 2013-12-31, filed 2014-02-14, with 31 holding rows worth $858,468,000.

Accession
0001144204-14-009252
Filed
2014-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2013

A holdings report, 31 entries on the cover page, a total value of $858,468,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $858,468,000 with VALUE read as thousands by filing date, 13F file number 028-12884. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ACADIA PHARMACEUTICALS INC004225108COM5,250,000$131,198,000thousands by filing datecall
ACHILLION PHARMACEUTICALS IN00448Q201COM23,366,007$77,552,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM5,227,272$72,607,000thousands by filing date
THERAPEUTICSMD INC88338N107COM11,660,108$60,749,000thousands by filing date
NOVAVAX INC670002104COMMON STOCK10,811,888$55,357,000thousands by filing date
OPHTHOTECH CORP683745103COM1,600,455$51,775,000thousands by filing date
PROTHENA CORP PLC SHSG72800108Stock1,641,167$43,524,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM3,000,000$41,670,000thousands by filing datecall
DYNAVAX TECHNOLOGIES CORP268158102COM17,883,954$35,053,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock4,347,456$33,041,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM1,169,898$29,236,000thousands by filing date
XENCOR INC98401F105COMMON STOCK2,725,000$24,907,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328601COM NEW4,869,261$23,080,000thousands by filing date
ARROWHEAD RESEARCH CORP042797209COM2,049,220$22,234,000thousands by filing date
DERMA SCIENCES INC249827502COM PAR $.011,994,876$21,585,000thousands by filing date
TESARO INC881569107COM700,000$19,768,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM752,438$12,769,000thousands by filing date
DYAX CORP26746E103COM1,619,697$12,204,000thousands by filing date
NEWLINK GENETICS CORP651511107COM500,000$11,005,000thousands by filing datecall
MIRATI THERAPEUTICS INC60468T105COM656,767$10,922,000thousands by filing date
ROCKWELL MED INC774374102COM1,000,000$10,440,000thousands by filing dateput
ACHILLION PHARMACEUTICALS IN00448Q201COM3,000,000$9,957,000thousands by filing datecall
BLUEBIRD BIO INC09609G100COM467,418$9,806,000thousands by filing date
OCERA THERAPEUTICS INC COM67552A108COM661,696$8,595,000thousands by filing date
Enzo Biochem Inc294100102Common Stock2,268,653$6,624,000thousands by filing date
MACROGENICS INC556099109COM199,398$5,469,000thousands by filing date
PSIVIDA CORP74440J101COM1,187,608$4,715,000thousands by filing date
DYAX CORP26746E103COM500,000$3,768,000thousands by filing datecall
MEI PHARMA INC55279B202COM NEW408,333$3,271,000thousands by filing date
CHELSEA THERAPEUTICS INTL LT163428105COM666,667$2,957,000thousands by filing date
CORONADO BIOSCIENCES INC21976U109COM1,000,000$2,630,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001144204-14-009252this filing2014-02-14acceptance time not in the bulk data set